Okla. Stat. tit. 63, § 63-3091.3

This is the official text of Okla. Stat. tit. 63, § 63-3091.3, part of Oklahoma’s Stat. tit. 63, — part of the compiled statutory law of Oklahoma, published by the state as "Stat. tit. 63,." Browse the sections below, each linked to its official government source.

Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.

Manufacturers' rights – Insurance coverage – Liability

Official statutory text

of patients' heirs.

A. A manufacturer of an investigational drug, biological

product or device may make available the manufacturer's

investigational drug, biological product or device to eligible

Oklahoma Statutes - Title 63. Public Health and Safety Page 1457

patients pursuant to the Right to Try Act. An investigational drug,

biological product or device may be made available through a

pharmacy. This act does not require that a manufacturer make

available an investigational drug, biological product or device to

an eligible patient.

B. A manufacturer may:

1. Provide an investigational drug, biological product or

device to an eligible patient without receiving compensation; or

2. Require an eligible patient to pay the costs of, or the

costs associated with, the manufacture of the investigational drug,

biological product or device.

C. A health insurance carrier may, but is not required to,

provide coverage for the cost of an investigational drug, biological

product or device.

D. An insurer may deny coverage to an eligible patient from the

time the eligible patient begins use of the investigational drug,

biological product or device through a period not to exceed six (6)

months from the time the investigational drug, biological product or

device is no longer used by the eligible patient; provided, that

coverage may not be denied for a preexisting condition and for

coverage for benefits which commenced prior to the time the eligible

patient begins use of such drug, biological product or device.

E. If a patient dies while being treated by an investigational

drug, biological product or device, the patient's heirs are not

liable for any outstanding debt related to the treatment or lack of

insurance due to the treatment.

Status: in_force · Read it on the official government site

Need a lawyer in Oklahoma?

Find a Oklahoma lawyer
About this page: Statute text is reproduced from official government publishers via the Open US Law dataset (Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine (Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.